Related Experiment Video
Updated: Jul 1, 2025
Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
Published on: July 5, 2024
Peptide derived from RAGE efficiently improves oocyte development through attenuating oxidative stress in oocytes of
Xiaojing Hou1, Zhonghui Ling1, Yaping Guo1
1Nanjing Women and Children's HealthCare Hospital, Women's Hospital of Nanjing Medical University, Nanjing, China.
Abstract:
Polycystic ovary syndrome (PCOS) is a common and complex endocrine disorder in reproductive-aged women that frequently leads to infertility due to poor oocyte quality. In this study, we identified a new active peptide (advanced glycation end products receptors RAGE344-355 ) from PCOS follicular fluid using mass spectrometry. We found that supplementing PCOS-like mouse oocytes with RAGE344-355 attenuated both meiotic defects and oxidative stress levels, ultimately preventing developmental defects. Additionally, our results suggest that RAGE344-355 may interact with eEF1a1 to mitigate oxidative meiotic defects in PCOS-like mouse oocytes. These findings highlight the potential for further clinical development of RAGE344-355 as a potent supplement and therapeutic option for women with PCOS. This research addresses an important clinical problem and offers promising opportunities for improving oocyte quality in PCOS patients.
Insights
Researchers discovered a peptide, RAGE344-355, in PCOS follicular fluid that improves oocyte quality. Supplementing with this peptide reduced defects and oxidative stress in PCOS-like mouse oocytes, offering therapeutic potential for infertility.
Area of Science:
- Endocrinology
- Reproductive Biology
- Molecular Medicine
Background:
- Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting reproductive-aged women.
- PCOS frequently causes infertility due to compromised oocyte quality.
Purpose of the Study:
- To identify novel therapeutic targets for improving oocyte quality in PCOS.
- To investigate the role of specific peptides in PCOS-related infertility.
Main Methods:
- Mass spectrometry was used to identify peptides in PCOS follicular fluid.
- PCOS-like mouse oocytes were supplemented with the identified peptide (RAGE344-355).
- Meiotic defects and oxidative stress levels were assessed.
Main Results:
- A novel active peptide, RAGE344-355, was identified from PCOS follicular fluid.
- Supplementation with RAGE344-355 attenuated meiotic defects and reduced oxidative stress in PCOS-like mouse oocytes.
- RAGE344-355 may interact with eEF1a1 to mitigate oxidative meiotic defects.
Conclusions:
- RAGE344-355 shows potential as a therapeutic agent to improve oocyte quality in women with PCOS.
- This peptide could offer a novel strategy to address infertility associated with PCOS.
- Further clinical development of RAGE344-355 is warranted for PCOS patients.
